10-Q: AbCellera Q3 2025: Pipeline Advances Amid Rising Losses

AbCellera Biologics reported increased revenue but a wider net loss in Q3 2025, while advancing two antibody therapies into Phase 1 clinical trials and a third into IND/CTA-enabling studies.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 38% to $8.955 million, driven by a 40% rise in research fees to $8.817 million.
• Net loss for the three months ended September 30, 2025, widened to $57.119 million, compared to $51.107 million in the prior year period.
• For the nine months ended September 30, 2025, total revenue increased by 27% to $30.275 million, primarily due to a significant increase in licensing revenue to $10.751 million (up 1302%).
• Net loss for the nine months ended September 30, 2025, increased to $137.467 million, from $128.647 million in the prior year period.
• Cash, cash equivalents, and marketable securities decreased by $129.9 million to $495.7 million as of September 30, 2025, from $625.6 million at December 31, 2024.
• Two internal antibody therapies, ABCL635 (vasomotor symptoms) and ABCL575 (atopic dermatitis), initiated Phase 1 clinical trials in Canada during the second half of 2025.
• A third program, ABCL688 (autoimmunity), advanced into IND/CTA-enabling studies in the second quarter of 2025.
• Cumulative partner-initiated program starts with downstream participation increased to 103, and cumulative molecules in the clinic reached 18.

Sentiment

Score: 4

Explanation: While operational progress in pipeline advancement is positive, the increasing net losses and significant reduction in cash and marketable securities indicate a worsening financial position. The lack of new milestone payments and continued high R&D spend without immediate offsetting revenue contribute to a cautious outlook, despite management's confidence in liquidity for the next 36 months.

Positives

• Total revenue for the three months ended September 30, 2025, increased by 38% to $8.955 million.
• Research fees for the three months ended September 30, 2025, increased by 40% to $8.817 million.
• Total revenue for the nine months ended September 30, 2025, increased by 27% to $30.275 million.
• Licensing revenue for the nine months ended September 30, 2025, significantly increased by 1302% to $10.751 million.
• Loss from operations improved for both the three-month period (from $93.663 million to $76.278 million) and the nine-month period (from $242.011 million to $188.521 million).
• Two internal antibody therapies, ABCL635 and ABCL575, initiated Phase 1 clinical trials in Canada in H2 2025 after receiving No Objection Letters from Health Canada.
• ABCL688, a third internal program, advanced into IND/CTA-enabling studies.
• Cumulative partner-initiated program starts with downstream participation increased by 8% to 103.
• Cumulative molecules in the clinic increased by 29% to 18.
• The company expects a significant reduction in investing cash flows after 2025, shifting capital allocation from building capabilities to using them.
• Management believes existing liquidity is sufficient for working capital and capital expenditure needs for at least the next 36 months, not anticipating additional external funding.
• The U.S. Court of Appeals for the Federal Circuit (CAFC) confirmed that all challenged claims of AbCellera's 408 Patent are not invalid in the Bruker litigation.

Negatives

• Net loss for the three months ended September 30, 2025, widened to $57.119 million from $51.107 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $137.467 million from $128.647 million in the prior year period.
• Cash, cash equivalents, and marketable securities decreased by $129.9 million to $495.7 million since December 31, 2024.
• No milestone payments were recognized in the nine months ended September 30, 2025, compared to $1.5 million in the prior year period.
• Research fees for the nine months ended September 30, 2025, decreased by 9% to $19.524 million.
• Research and development expenses increased by 34% in Q3 2025 and 13% for the nine months ended September 30, 2025, reflecting continued investment and headcount increases.
• Interest income decreased by 30% in Q3 2025 and 25% for the nine months ended September 30, 2025, due to lower cash balances and interest rate yields.
• Other income decreased significantly due to a $16.5 million gain recognized on the disposal of a non-marketable security in 2024, which did not recur in 2025.
• The company has incurred losses in 2025 and expects to incur losses for the foreseeable future, with no marketed proprietary products yet.

Risks

• Incurred losses in 2025 and may not generate sufficient revenue to achieve profitability, expecting losses for the foreseeable future.
• Quarterly and annual operating results have fluctuated significantly and may continue to do so, making future predictions difficult.
• Commercial success is dependent on the quality of antibody discovery and development capabilities, advancement of internal programs, and acceptance by partners.
• Development of biological molecules is inherently uncertain, with no guarantee of marketing approval or commercial viability for any antibody drug candidates.
• Partners have significant discretion in making announcements about partnership status, which could cause share price declines due to unexpected results.
• May not be able to file applications or amendments for additional clinical trials on expected timelines, and regulatory bodies may not permit progression.
• No marketed proprietary products and no independent clinical development experience, making it difficult to assess ability to independently develop and monetize future product candidates.
• Limited number of product candidates; failure to obtain regulatory approval or significant delays would materially adversely affect the business.
• Long-term prospects depend on discovering, developing, and commercializing additional product candidates, which may fail or suffer delays.
• Faces significant competition from more effective, safer, or less expensive competitor products.
• Upgrading and integrating business systems (e.g., new ERP system) could result in implementation issues and business disruptions.
• Inability to obtain and maintain sufficient intellectual property protection could allow competitors to develop similar technologies.
• Involvement in lawsuits to protect or enforce intellectual property (e.g., Bruker, Schrader) could be expensive, time-consuming, and unsuccessful.
• Failure to maintain proper and effective internal control over financial reporting could harm operating results.
• Sales of a substantial number of common shares in the public market could cause share price to fall significantly.
• Impairment charges pertaining to goodwill, identifiable intangible assets, or other long-lived assets could have an adverse non-cash accounting impact.
• Market price of common shares may be volatile, leading to potential investment loss.
• May need to raise additional capital, which could result in dilution or restrictive covenants, despite current liquidity projections.
• Unstable market and economic conditions (e.g., military conflicts, banking system disruptions, inflation) may adversely affect business and share price.
• Resource allocation decisions may cause the company to forgo more profitable opportunities.
• Reliance on partners to meet contractual obligations and achieve milestones.
• Investments in R&D are inherently risky and may not yield sufficient returns.
• Clinical trials are expensive, time-consuming, difficult to design, and involve uncertain outcomes, with a high rate of attrition.
• Product candidates may have undesirable side effects, delaying or preventing marketing approval or limiting sales.
• Approved products may not achieve broad market acceptance among physicians, patients, and payors.
• Difficulty obtaining regulatory approval or commercialization outside the United States.
• Manufacturing difficulties or reliance on single-source suppliers could delay or prevent supply.
• Government price controls and healthcare reform measures could adversely affect pricing and profitability.
• Public health outbreaks and pandemics could disrupt clinical trials and business activities.
• Exposure to anti-kickback, fraud and abuse, false claims, and privacy laws.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, and anti-corruption laws.
• Use of biological and hazardous materials requires expertise and expense, with risk of claims.
• Reliance on animals for discovery could lead to disease, death, or adverse publicity.
• Acquisition integration risks and potential future impairments (Trianni, TetraGenetics).
• Billing and collections processing activities are time-consuming and subject to delays or non-compliance.
• Operating facilities could be damaged or inoperable by disasters.
• Inadequate insurance coverage.
• Cybersecurity breaches could compromise sensitive information and expose to liability.
• Loss of senior management or inability to attract/retain talent.
• Restructuring activities may be disruptive or ineffective.
• Foreign currency exchange rate risks.
• Potential adverse U.S. federal income tax consequences if classified as a Controlled Foreign Corporation (CFC) or Passive Foreign Investment Company (PFIC).
• Tax authorities may disagree with tax positions.
• Changes in tax law.
• Disclosure controls may not prevent or detect all errors or fraud.
• Canadian corporate laws may affect shareholder rights differently than U.S. laws.
• Anti-takeover provisions in articles and Canadian legislation.
• Difficulty serving legal process or enforcing judgments against the company due to Canadian incorporation.
• Estimates or judgments relating to critical accounting policies may prove incorrect.
• Reliance on securities/industry analysts for share price and trading volume.
• Adverse developments in the financial services industry could affect liquidity.

Future Outlook

The company expects to continue significant investments in research and development and incur substantial expenses for the foreseeable future. However, with the completion of its clinical manufacturing facility and corporate headquarters in 2025, a significant reduction in investing cash flows is anticipated, shifting capital allocation towards utilizing capabilities to build its pipeline of medicines. Management believes existing liquidity will be sufficient to meet working capital and capital expenditure needs for at least the next 36 months, without requiring additional external funding. Phase 1 data for ABCL635 is expected in mid-2026, and an IND/CTA submission for ABCL688 is anticipated in 2026.

Management Comments

• "We are a team of scientists, engineers, and business professionals focused on discovering and developing first-in-class and best-in-class antibody-based medicines for indications with high unmet medical need."
• "We think deeply about capital allocation and strive to maximize long-term value while mitigating the risks that are inherent in drug development."
• "We look for opportunities where we believe low-risk investments in building technology and operational efficiency can create a sustained competitive advantage and drive long-term value by making biologics drug development faster and more efficient."
• "The programs align with the Company's strategy of building value, both through strategic partnerships, and through internal discovery and development of potential first-in-class and best-in-class antibody therapies."
• "Based on our current business plan, we believe that our available liquidity from existing cash, cash equivalents, marketable securities, loan receivables, and government contributions, will be sufficient to meet our working capital and capital expenditure needs and do not anticipate the need of additional external funding over at least the next 36 months following the date of this report."
• "With the completion of these large platform investments, we expect a significant reduction in investing cash flows, shifting our capital allocation from building capabilities to using them as we execute our strategy of building on our pipeline of first-in-class and best-in-class medicines."

Industry Context

The company operates in the highly competitive and rapidly changing life sciences industry, focusing on antibody drug discovery and development. Its strategy involves leveraging technology platforms for both internal programs and strategic partnerships, aiming for first-in-class and best-in-class antibody-based medicines. The industry faces challenges from biosimilar competition and evolving healthcare reform measures, such as the Inflation Reduction Act of 2022, which impact drug pricing and reimbursement. The company's model emphasizes downstream payments (milestones and royalties) from partners, a common structure in biotech collaborations.

Comparison to Industry Standards

• The increase in cumulative molecules in the clinic to 18 and partner-initiated program starts to 103 indicates strong pipeline progression and partner engagement, which are key performance indicators in the biotechnology industry.
• The advancement of two internal programs (ABCL635, ABCL575) into Phase 1 clinical trials and a third (ABCL688) into IND/CTA-enabling studies demonstrates successful internal R&D execution, aligning with the industry trend of biotechs building proprietary pipelines.
• The company's reliance on downstream milestone and royalty payments from partners is a standard business model in antibody discovery, where the upfront fees are typically smaller than the potential long-term value.
• The significant R&D investment and ongoing losses are typical for clinical-stage biotechnology companies focused on drug development, as the path to commercialization is long, costly, and uncertain.

Corporate Governance

Legal Proceedings

• **Patent Infringement Litigation against Bruker Cellular Analysis:** The company filed a complaint in July 2020, alleging infringement of multiple U.S. patents by Bruker's Beacon Optofluidic System. Fact discovery has closed, and an eight-day jury trial is scheduled for January 2026. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker's arguments regarding U.S. Patent No. 10,087,408, and the U.S. Court of Appeals for the Federal Circuit (CAFC) confirmed that all challenged claims of AbCellera's 408 Patent are not invalid in May 2025.
• **Civil Litigation: Sabariah Schrader, Executrix of the Estate of John William Schrader et al. v. Carl Lars Genghis Hansen, et al.:** A lawsuit filed in October 2022 in the Supreme Court of British Columbia alleging breach of an implied partnership/joint venture and patent infringement of Canadian patent No. 2,655,511. The company filed a Notice of Application to dismiss certain affiliates for lack of jurisdiction, with no hearing date set. The company believes the claim is meritless.

Related Party Transactions

• The company has entered into two 50% joint ventures, Dayhu JV and Beedie JV, for the construction of future office and laboratory headquarters.
• As of September 30, 2025, the company had a loan receivable balance of $33.1 million with Dayhu JV and $38.2 million with Beedie JV.
• Incurred lease expense of $1.3 million (Q3 2025) and $3.8 million (YTD Sep 30, 2025) to Dayhu JV.
• Incurred lease expense of $1.7 million (Q3 2025) and $2.8 million (YTD Sep 30, 2025) to Beedie JV.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future equity issuances, volatility in share price, and no anticipated cash dividends. The company's principal shareholders and management own a significant percentage of shares, influencing shareholder approval matters.
• **Employees:** The November 2023 restructuring reduced headcount by approximately 10%, potentially impacting morale and increasing attrition risk. The company's success depends on attracting and retaining highly skilled scientific and engineering personnel.
• **Partners:** The company's future revenue is highly reliant on partners successfully developing and commercializing antibodies, and meeting contractual obligations for milestone and royalty payments.
• **Customers:** Potential impact from healthcare reform measures and government price controls on the pricing and market acceptance of future approved products.
• **Regulatory Bodies:** The company's ability to advance programs and commercialize products is subject to regulatory approvals and compliance with evolving healthcare laws and regulations.

Next Steps

• Continue Phase 1 clinical trials for ABCL635 and ABCL575.
• Present ABCL635 Phase 1 data in mid-2026.
• Anticipate IND/CTA submission for ABCL688 in 2026.
• Complete final large platform investments in clinical manufacturing facility and corporate headquarters in 2025.
• Shift capital allocation from building capabilities to using them for pipeline execution.
• Continue to protect intellectual property, including the jury trial against Bruker Cellular Analysis scheduled for January 2026.
• Proceed with seeking dismissal of certain Company affiliates from the Schrader litigation.
• Evaluate the impact of ASU 2023-09 on financial statements, effective for fiscal years beginning after December 15, 2024.

Key Dates

Recommendation

AbCellera is making significant operational strides by advancing multiple internal antibody programs into clinical trials and expanding its partner-initiated pipeline. The completion of major infrastructure investments in 2025 is expected to reduce future capital expenditures, which is a positive long-term signal. However, these operational positives are currently overshadowed by increasing net losses and a notable decline in cash and marketable securities. The absence of new milestone payments in the current period, coupled with ongoing high R&D expenses and significant legal proceedings, introduces financial uncertainty. While management projects sufficient liquidity for the next 36 months, the path to profitability remains distant and subject to substantial clinical and commercial risks inherent in drug development. Therefore, a 'hold' recommendation is appropriate, acknowledging the long-term potential while recognizing the near-term financial challenges and execution risks.

Keywords

Antibody Discovery, Biologics, Clinical Trials, Drug Development, Biotechnology, SEC Filing, 10-Q, Financial Results, Research & Development, ABCL635, ABCL575, ABCL688, Phase 1, Vasomotor Symptoms, Atopic Dermatitis, Autoimmunity, Intellectual Property, Litigation, Corporate Governance, Cash Flow, Revenue, Net Loss, Canada, Health Canada, ERP System